Intercept price target raised to $400 from $60 at Citigroup Citigroup raised its price target for Intercept shares to $400 from $60 saying it still sees value in the stock despite yesterday's 300% gain. Citi believes the company's $5.4B market capitalization does not reflect its multi-billion dollar opportunity in non-alcoholic steatohepatitis/ liver fibrosis. The firm thinks Intercept's obeticholic acid could top $5B a year in sales and keeps a Buy rating on the stock.
News For ICPT From The Last 14 Days
Check below for free stories on ICPT the last two weeks.